Log in

NASDAQ:ISRIsoRay Stock Price, Forecast & News

-0.02 (-3.79 %)
(As of 04/3/2020 04:00 PM ET)
Today's Range
Now: $0.51
50-Day Range
MA: $0.70
52-Week Range
Now: $0.51
Volume269,774 shs
Average Volume598,526 shs
Market Capitalization$34.33 million
P/E RatioN/A
Dividend YieldN/A
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.62 out of 5 stars

Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Current SymbolNASDAQ:ISR



Sales & Book Value

Annual SalesN/A



Market Cap$34.33 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.

IsoRay (NASDAQ:ISR) Frequently Asked Questions

How has IsoRay's stock been impacted by COVID-19 (Coronavirus)?

IsoRay's stock was trading at $0.6706 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ISR shares have decreased by 24.3% and is now trading at $0.5075. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IsoRay?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IsoRay.

When is IsoRay's next earnings date?

IsoRay is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for IsoRay.

How were IsoRay's earnings last quarter?

IsoRay, Inc. (NASDAQ:ISR) announced its earnings results on Tuesday, February, 11th. The company reported ($0.01) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.01). The business earned $2.21 million during the quarter, compared to the consensus estimate of $2.39 million. View IsoRay's earnings history.

Has IsoRay been receiving favorable news coverage?

Media coverage about ISR stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. IsoRay earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutIsoRay.

Who are some of IsoRay's key competitors?

What other stocks do shareholders of IsoRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IsoRay investors own include Nutra Pharma (NPHC), Generex Biotechnology (GNBT), BRK (BRKK), Ibio (IBIO), CAN-FITE BIOPHA/S (CANF), BlackBerry (BB), Workhorse Group (WKHS), Tonix Pharmaceuticals (TNXP), Miragen Therapeutics (MGEN) and Moleculin Biotech (MBRX).

Who are IsoRay's key executives?

IsoRay's management team includes the following people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 58)
  • Mr. Michael L. Krachon, VP of Sales & Marketing (Age 49)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 54)
  • Mr. Jonathan R. Hunt, CFO & Co-Principal Financial Officer (Age 53)
  • Ms. Jennifer Streeter, Interim COO & VP of HR (Age 50)

What is IsoRay's stock symbol?

IsoRay trades on the NASDAQ under the ticker symbol "ISR."

How do I buy shares of IsoRay?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IsoRay's stock price today?

One share of ISR stock can currently be purchased for approximately $0.51.

How big of a company is IsoRay?

IsoRay has a market capitalization of $34.33 million. IsoRay employs 43 workers across the globe. View additional information about IsoRay.

What is IsoRay's official website?

The official website for IsoRay is http://www.isoray.com/.

How can I contact IsoRay?

The company can be reached via phone at 509-375-1202.

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel